India Alternative Protein Fund
-
DATABASE (763)
-
ARTICLES (339)
San Francisco-based BOND is a spinoff of Kleiner Perkins and its original digital growth fund. BOND was launched in 2019, investing across market segments and geographies. To date, it has raised two funds totaling $3.3bn and currently has 32 portfolio companies. Its recent investments include Portuguese home physiotherapy tech SWORD, the world’s fastest-growing musculoskeletal solution, in June 2021 in a $85m Series C funding round; and co-leading the July 2021 $50m Series B round of US fungi-based alt-protein startup Meati Foods.
San Francisco-based BOND is a spinoff of Kleiner Perkins and its original digital growth fund. BOND was launched in 2019, investing across market segments and geographies. To date, it has raised two funds totaling $3.3bn and currently has 32 portfolio companies. Its recent investments include Portuguese home physiotherapy tech SWORD, the world’s fastest-growing musculoskeletal solution, in June 2021 in a $85m Series C funding round; and co-leading the July 2021 $50m Series B round of US fungi-based alt-protein startup Meati Foods.
The venture capital arm of semiconductor and telecom equipment giant Qualcomm is a San-Diego investor focusing on VR, robotics, IoT, cloud and digital health companies in the US, Europe, Israel, China, Korea and India.
The venture capital arm of semiconductor and telecom equipment giant Qualcomm is a San-Diego investor focusing on VR, robotics, IoT, cloud and digital health companies in the US, Europe, Israel, China, Korea and India.
Co-founder of Therapixal
Pierre Fillard is Chief Science Officer and co-founder of Therapixel, creator of AI-powered breast cancer screening and diagnosis software MammoScreen. At Therapixel, he previously held the positions of CEO and CTO. Before founding Therapixel, Fillard was a senior research scientist at INRIA (National Institute for Research in Digital Science and Technology), where he focused on medical imaging and image processing. He has also been a visiting lecturer at CPE Lyon, a research associate at the French Alternative Energies and Atomic Agencies Commission, a PhD candidate at INRIA, and a research assistant at the University of North Carolina. He has a diploma from the HEC School of Management, a master’s in science, mathematics and computer science from the Université Jean Monnet Saint-Etienne and a degree in engineering, computer science, and applied mathematics from the Ecole Supérieure de Chimie Physique Electronique de Lyon.
Pierre Fillard is Chief Science Officer and co-founder of Therapixel, creator of AI-powered breast cancer screening and diagnosis software MammoScreen. At Therapixel, he previously held the positions of CEO and CTO. Before founding Therapixel, Fillard was a senior research scientist at INRIA (National Institute for Research in Digital Science and Technology), where he focused on medical imaging and image processing. He has also been a visiting lecturer at CPE Lyon, a research associate at the French Alternative Energies and Atomic Agencies Commission, a PhD candidate at INRIA, and a research assistant at the University of North Carolina. He has a diploma from the HEC School of Management, a master’s in science, mathematics and computer science from the Université Jean Monnet Saint-Etienne and a degree in engineering, computer science, and applied mathematics from the Ecole Supérieure de Chimie Physique Electronique de Lyon.
Fondazione Marche, founded in 2009, is a private, non-profit business promotion organization that operates exclusively in the Italian territory of the Marche Region in central-eastern Italy. It is based in the regional capital Ancona. The organization was established by local business leaders in association with banks Banca Popolare di Ancona and BPU, who funded the company with €15m. It invests across sectors and technologies, with both tech and non-tech startups supported. Its most recent investment to date was in Italo-Spanish insect protein flour manufacturer Nutrinsect, with a €350,000 pre-seed investment in May 2020.
Fondazione Marche, founded in 2009, is a private, non-profit business promotion organization that operates exclusively in the Italian territory of the Marche Region in central-eastern Italy. It is based in the regional capital Ancona. The organization was established by local business leaders in association with banks Banca Popolare di Ancona and BPU, who funded the company with €15m. It invests across sectors and technologies, with both tech and non-tech startups supported. Its most recent investment to date was in Italo-Spanish insect protein flour manufacturer Nutrinsect, with a €350,000 pre-seed investment in May 2020.
Mitchell Presser is a New York-based lawyer. He is currently co-chair of global law service Morrison & Foerster’s Global Corporate Department and a partner in the firm’s M&A and Private Equity group, advising on agriculture, amongst other areas. He previously was a founding partner of Paine Schwartz, a US-based $1.2 bn private equity firm specializing in sustainable food chain investing from 2006 to 2014. His sole disclosed angel investment to date was an undisclosed sum in the pre-seed funding of NovoNutrients, the US-based biotech producer of alt-protein from fermentation using CO2 and other emissions,
Mitchell Presser is a New York-based lawyer. He is currently co-chair of global law service Morrison & Foerster’s Global Corporate Department and a partner in the firm’s M&A and Private Equity group, advising on agriculture, amongst other areas. He previously was a founding partner of Paine Schwartz, a US-based $1.2 bn private equity firm specializing in sustainable food chain investing from 2006 to 2014. His sole disclosed angel investment to date was an undisclosed sum in the pre-seed funding of NovoNutrients, the US-based biotech producer of alt-protein from fermentation using CO2 and other emissions,
Advisor, board member, co-founder of NovoNutrients
Brian Sefton has been co-founder, a board member and a part-time advisor at NovoNutrients, a San Francisco-based biotech manufacturer of alt-protein produced from fermentation and CO2 since it was founded in 2017. In 2009, he co-founded research entity Oakbio, from which NovoNutrients evolved, and was its President and CTO. Sefton was CTO and President at NovoNutrients and also co-CEO and Chief Scientist at Oakbio until 2021 when he became the CEO at San Francisco-based fermentation commercialization startup Sincarne. Between 2005 and 2011, Sefton was also CEO at pharma research company Pharmadyn, working on drugs development for Alzheimer's Disease, and, for three of those years, was also Managing Partner of Stratsyn, a consultancy specializing in creation, development, management and fund raising for not-for-profit organizations. Sefton’s earlier posts include: directing nanotechnology commercialization and investment company Nanosig for three years, CEO of Silicon Valley’s Fastlane, a high-profile pioneer in real-time network traffic and security analysis for six years; and, simultaneously, being CEO at Bluebox Communications, developing high-end network security applications and appliances for Fortune 500 companies and the US government.Sefton holds an MBA from Santa Clara University in California and a bachelor’s degree in biochemistry from the University of California, Berkeley
Brian Sefton has been co-founder, a board member and a part-time advisor at NovoNutrients, a San Francisco-based biotech manufacturer of alt-protein produced from fermentation and CO2 since it was founded in 2017. In 2009, he co-founded research entity Oakbio, from which NovoNutrients evolved, and was its President and CTO. Sefton was CTO and President at NovoNutrients and also co-CEO and Chief Scientist at Oakbio until 2021 when he became the CEO at San Francisco-based fermentation commercialization startup Sincarne. Between 2005 and 2011, Sefton was also CEO at pharma research company Pharmadyn, working on drugs development for Alzheimer's Disease, and, for three of those years, was also Managing Partner of Stratsyn, a consultancy specializing in creation, development, management and fund raising for not-for-profit organizations. Sefton’s earlier posts include: directing nanotechnology commercialization and investment company Nanosig for three years, CEO of Silicon Valley’s Fastlane, a high-profile pioneer in real-time network traffic and security analysis for six years; and, simultaneously, being CEO at Bluebox Communications, developing high-end network security applications and appliances for Fortune 500 companies and the US government.Sefton holds an MBA from Santa Clara University in California and a bachelor’s degree in biochemistry from the University of California, Berkeley
WWF-backed biotech Oceanium has developed a biorefinery that transforms seaweed into alt-proteins and compostable packaging that will soon be launched commercially.
WWF-backed biotech Oceanium has developed a biorefinery that transforms seaweed into alt-proteins and compostable packaging that will soon be launched commercially.
Backed by Temasek Holdings and United Overseas Bank, InnoVen Capital has offices in Mumbai, Singapore and China. InnoVen Capital is the largest provider of venture debt to venture capital firms in India. The firm’s China office was established in April 2017.
Backed by Temasek Holdings and United Overseas Bank, InnoVen Capital has offices in Mumbai, Singapore and China. InnoVen Capital is the largest provider of venture debt to venture capital firms in India. The firm’s China office was established in April 2017.
Founded in 2017, Starlight Ventures is a venture capital firm based in Miami, Florida. Investing mainly in US-based startups, the VC currently has 29 startups in its portfolio including enterprises involved in alternative energy, carbon reduction or replacement and alt-proteins sectors. In 2020, the firm joined investment rounds for US deep-tech aerospace startup InterCosmos in July and the $84m Series A for fusion energy tech Commonwealth Fusion in May.
Founded in 2017, Starlight Ventures is a venture capital firm based in Miami, Florida. Investing mainly in US-based startups, the VC currently has 29 startups in its portfolio including enterprises involved in alternative energy, carbon reduction or replacement and alt-proteins sectors. In 2020, the firm joined investment rounds for US deep-tech aerospace startup InterCosmos in July and the $84m Series A for fusion energy tech Commonwealth Fusion in May.
Chairman of the Board, co-founder, co-inventor of NovoNutrients
Russell J. Howard has been co-founder and chairman of the board at NovoNutrients, a San Francisco biotech manufacturer of alt-protein produced using fermentation and CO2, and the research company Oakbio, since the latter’s foundation in 2009. During this period, for a year, Howard also worked as head of commercial strategy at Genome.One, a genetics startup. Howard is also on the board of executives of two Australian pharma companies, Immutep and NeuClone. Previously, between 1997 and 2009, he was CEO at California-based Maxygen, dedicated to the commercialization of molecular breeding and gene shuffling in protein. The year before that, Howard was president and scientific director at global pharma giant GSK in Santa Clara, and between 1994 and 1996, he held the same position at AFFYMAX Research Institute, working on new drugs research. Howard also held long-term research positions, heading up the laboratory at Palo Alto’s DNAX Research Institute of Molecular & Cellular Biology for six years, and earlier spent nine years at Bethesda’s National Institute of Allergy and Infectious Diseases (NIAID) working on identifying new malarial pathogens. The doctor of biochemistry from the University of Melbourne has over 140 peer-reviewed publications. Following his studies, Howard spent three years undertaking postdoctoral research at Australia’s WEHI (formerly the Walter and Eliza Hall Institute of Medical Research).
Russell J. Howard has been co-founder and chairman of the board at NovoNutrients, a San Francisco biotech manufacturer of alt-protein produced using fermentation and CO2, and the research company Oakbio, since the latter’s foundation in 2009. During this period, for a year, Howard also worked as head of commercial strategy at Genome.One, a genetics startup. Howard is also on the board of executives of two Australian pharma companies, Immutep and NeuClone. Previously, between 1997 and 2009, he was CEO at California-based Maxygen, dedicated to the commercialization of molecular breeding and gene shuffling in protein. The year before that, Howard was president and scientific director at global pharma giant GSK in Santa Clara, and between 1994 and 1996, he held the same position at AFFYMAX Research Institute, working on new drugs research. Howard also held long-term research positions, heading up the laboratory at Palo Alto’s DNAX Research Institute of Molecular & Cellular Biology for six years, and earlier spent nine years at Bethesda’s National Institute of Allergy and Infectious Diseases (NIAID) working on identifying new malarial pathogens. The doctor of biochemistry from the University of Melbourne has over 140 peer-reviewed publications. Following his studies, Howard spent three years undertaking postdoctoral research at Australia’s WEHI (formerly the Walter and Eliza Hall Institute of Medical Research).
CEO and founder of Mycorena
Ramkumar Nair graduated in biotechnology at the Cochin University of Science and Technology in Kerala before going to Sweden for postgrad studies in 2013.During his PhD in industrial biotechnology at the University of Borås, he embarked on a research project to create fungi-based proteins from discarded sidestreams generated by food producers. After extensive research in 2017, he founded Mycorena in Gothenburg to produce mycoproteins using fermentation technology.The startup’s first commercial product, Promyc, is now being sold to global food companies as a more sustainable and nutritional alt-protein compared to traditional plant-based proteins.
Ramkumar Nair graduated in biotechnology at the Cochin University of Science and Technology in Kerala before going to Sweden for postgrad studies in 2013.During his PhD in industrial biotechnology at the University of Borås, he embarked on a research project to create fungi-based proteins from discarded sidestreams generated by food producers. After extensive research in 2017, he founded Mycorena in Gothenburg to produce mycoproteins using fermentation technology.The startup’s first commercial product, Promyc, is now being sold to global food companies as a more sustainable and nutritional alt-protein compared to traditional plant-based proteins.
Co-Founder of Lemonilo
Michigan University graduate Ronald Wijaya has a bachelor’s and a master’s in Industrial Engineering. Upon graduation, Wijaya worked at Indonesian confectionery and beverage company PT. United Family Food, first as an Operations Manager and then as a Project Manager. He was also a volunteer on a missionary trip to Kolkata, India, to help underprivileged children and youths. Wijaya continues to work in Lemonilo, the health food company that was born from Konsula’s pivot, and is currently co-CEO of the company.
Michigan University graduate Ronald Wijaya has a bachelor’s and a master’s in Industrial Engineering. Upon graduation, Wijaya worked at Indonesian confectionery and beverage company PT. United Family Food, first as an Operations Manager and then as a Project Manager. He was also a volunteer on a missionary trip to Kolkata, India, to help underprivileged children and youths. Wijaya continues to work in Lemonilo, the health food company that was born from Konsula’s pivot, and is currently co-CEO of the company.
Founded in 2018, Kale United is a Stockholm-based ethical investor with an overriding interest in plant-based technologies. It raises funds from crowd campaigns and currently has a portfolio of 30 companies, mostly Swedish alternative meat startups. It had crowdfunded €1.34m by April 2020 for its portfolio of companies from three separate campaigns. It also has a portfolio of plant-based public shares and features a team of vegan expert investors and business leaders. Its founder, Måns Ullerstam, owns a third of the company. He is also CEO of local vegetarian food producer startup Astrid och Aporna.
Founded in 2018, Kale United is a Stockholm-based ethical investor with an overriding interest in plant-based technologies. It raises funds from crowd campaigns and currently has a portfolio of 30 companies, mostly Swedish alternative meat startups. It had crowdfunded €1.34m by April 2020 for its portfolio of companies from three separate campaigns. It also has a portfolio of plant-based public shares and features a team of vegan expert investors and business leaders. Its founder, Måns Ullerstam, owns a third of the company. He is also CEO of local vegetarian food producer startup Astrid och Aporna.
Innovative Sports Investment (ISIN) focuses on the eSports sector, backing startups that develop disruptive technologies for athletes and investors through seed investment rounds. Led by Javier Morales, Ander Iñarrairaegui and Javier Colás, the firm also has international offices in Japan, South Korea, India, the US and Argentina.
Innovative Sports Investment (ISIN) focuses on the eSports sector, backing startups that develop disruptive technologies for athletes and investors through seed investment rounds. Led by Javier Morales, Ander Iñarrairaegui and Javier Colás, the firm also has international offices in Japan, South Korea, India, the US and Argentina.
American financial services company Capital Group was established in 1931. As one of the world’s oldest investment management firms, it has over $2tn assets under management. Major known investments include arms and aerospace firm BAE Systems and British American Tobacco. In 1992, Capital Group established Capital Group Private Markets, which specializes in alternative private equity and venture capital investments. This organization has invested in companies like ride-hailing firms Gojek and Didi Chuxing, Philippines media conglomerate ABS-CBN, and more.
American financial services company Capital Group was established in 1931. As one of the world’s oldest investment management firms, it has over $2tn assets under management. Major known investments include arms and aerospace firm BAE Systems and British American Tobacco. In 1992, Capital Group established Capital Group Private Markets, which specializes in alternative private equity and venture capital investments. This organization has invested in companies like ride-hailing firms Gojek and Didi Chuxing, Philippines media conglomerate ABS-CBN, and more.
Big Idea Ventures Founder Andrew D Ive: Asia will lead cell-based meat innovation
In a wide-ranging interview, the managing general partner of the US- and Singapore-based foodtech investor also expounds on his goal to extend sustainability to the rest of the food sector, combining good returns with doing good
String Bio: Asia's first startup to harness methane gas for protein production
Using bacteria to turn the harmful greenhouse gas into a purer form of protein, String Bio is raising Series B funding to scale production
Future Food Asia 2021: Potential of pulses in the alt-protein space
Asia presents a unique opportunity for pulses as people in the region, who traditionally fractionated pulses for starch, now see protein as a useful byproduct
Mycorena: Fungi-based vegan protein challenging traditional plant-based ingredients
Award-winning Swedish biotech startup is scaling production of mycoprotein to become a key player in the emerging market for functional proteins
New Food Invest: Growing an alternative protein business in Asia
With more than 4bn people, Asia presents unique opportunities and challenges to alternative protein startups. Four leading entrepreneurs shared their experiences at the recent New Food Invest conference
Good Startup: Alt-protein products can be better than real meat
The investor of Eat Just, Ripple Foods and more expects its portfolio companies will exit in the next four to six years, mostly through acquisition
New Food Invest: Plant-based cheese, the next investment boom?
With alt-protein startups experiencing a global funding boom, industry experts and investors share their views about emerging trends in diverse food sectors
Sophie's Bionutrients: Alternative protein from microalgae
Inspired by fish in the ocean, the startup developed microalgae-based flour that can take on unlimited forms, textures or colors to make almost any alt protein product
Dao Foods: Grooming and betting on China's rising alternative protein startups
How can businesses involve Chinese consumers in the environmental cause, even if it isn’t a priority for them? For that, the impact investor-incubator Dao Foods has got its philosophy-led strategy figured out
SWITCH Singapore: Sustainability startups see growing demand from corporates
Sophie’s BioNutrients, Ubiik and Intello Labs also note new trends in technology and supply chain arising from the Covid-19 pandemic, across the food, manufacturing and e-commerce sectors
Singapore, the place to start and grow a cellular agriculture startup
A country that imports over 90% of its food supply, Singapore has turned to foodtech, including cellular agriculture, to safeguard food security, supported by proactive regulators
Plant-based eggs (Part II): The foodtech startups to watch
Here’s a shortlist of the foodtech startups to watch in the global vegan egg market
NovoNutrients: Tackling the dual problems of CO2 emissions and over-fishing
The first to transform CO2 to fish food, NovoNutrients is trialing with industry giants Skretting and Chevron, and will soon raise Series A funding
Xampla: Making strong, low-cost biodegradable plastic from peas
Inspired by the strength of spider silk, the Cambridge University spinoff has produced a plant-based, completely compostable alternative to microplastics
Future Food Asia 2021 announces finalists for $100,000 prize
Ten startups from agrifood tech and cleantech sectors will pitch during the five-day conference, are also eligible for two more prizes from sponsors Cargill and Thai Wah
Sorry, we couldn’t find any matches for “India Alternative Protein Fund”.
